ANIP Relative Valuation
ANIP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANIP is overvalued; if below, it's undervalued.
Historical Valuation
ANI Pharmaceuticals Inc (ANIP) is now in the Fair zone, suggesting that its current forward PE ratio of 10.67 is considered Fairly compared with the five-year average of 12.84. The fair price of ANI Pharmaceuticals Inc (ANIP) is between 72.85 to 122.97 according to relative valuation methord.
Relative Value
Fair Zone
72.85-122.97
Current Price：82.06
Fair
10.54
PE
1Y
3Y
5Y
Trailing
Forward
8.69
EV/EBITDA
ANI Pharmaceuticals Inc. (ANIP) has a current EV/EBITDA of 8.69. The 5-year average EV/EBITDA is 9.49. The thresholds are as follows: Strongly Undervalued below 5.97, Undervalued between 5.97 and 7.73, Fairly Valued between 11.25 and 7.73, Overvalued between 11.25 and 13.01, and Strongly Overvalued above 13.01. The current Forward EV/EBITDA of 8.69 falls within the Historic Trend Line -Fairly Valued range.
27.37
EV/EBIT
ANI Pharmaceuticals Inc. (ANIP) has a current EV/EBIT of 27.37. The 5-year average EV/EBIT is 65.59. The thresholds are as follows: Strongly Undervalued below -480.33, Undervalued between -480.33 and -207.37, Fairly Valued between 338.54 and -207.37, Overvalued between 338.54 and 611.50, and Strongly Overvalued above 611.50. The current Forward EV/EBIT of 27.37 falls within the Historic Trend Line -Fairly Valued range.
1.89
PS
ANI Pharmaceuticals Inc. (ANIP) has a current PS of 1.89. The 5-year average PS is 1.87. The thresholds are as follows: Strongly Undervalued below 1.25, Undervalued between 1.25 and 1.56, Fairly Valued between 2.18 and 1.56, Overvalued between 2.18 and 2.49, and Strongly Overvalued above 2.49. The current Forward PS of 1.89 falls within the Historic Trend Line -Fairly Valued range.
10.72
P/OCF
ANI Pharmaceuticals Inc. (ANIP) has a current P/OCF of 10.72. The 5-year average P/OCF is 13.17. The thresholds are as follows: Strongly Undervalued below -41.90, Undervalued between -41.90 and -14.36, Fairly Valued between 40.71 and -14.36, Overvalued between 40.71 and 68.24, and Strongly Overvalued above 68.24. The current Forward P/OCF of 10.72 falls within the Historic Trend Line -Fairly Valued range.
13.35
P/FCF
ANI Pharmaceuticals Inc. (ANIP) has a current P/FCF of 13.35. The 5-year average P/FCF is 12.71. The thresholds are as follows: Strongly Undervalued below -5.34, Undervalued between -5.34 and 3.69, Fairly Valued between 21.74 and 3.69, Overvalued between 21.74 and 30.77, and Strongly Overvalued above 30.77. The current Forward P/FCF of 13.35 falls within the Historic Trend Line -Fairly Valued range.
ANI Pharmaceuticals Inc (ANIP) has a current Price-to-Book (P/B) ratio of 3.42. Compared to its 3-year average P/B ratio of 2.78 , the current P/B ratio is approximately 22.86% higher. Relative to its 5-year average P/B ratio of 2.45, the current P/B ratio is about 39.84% higher. ANI Pharmaceuticals Inc (ANIP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 4.87%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 2.43% , the current FCF yield is about -100.00% lower.
3.38
P/B
Median3y
2.78
Median5y
2.45
9.00
FCF Yield
Median3y
4.87
Median5y
2.43
Competitors Valuation Multiple
The average P/S ratio for ANIP's competitors is 0.00, providing a benchmark for relative valuation. ANI Pharmaceuticals Inc Corp (ANIP) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 53.58%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ANIP increased by 47.92% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 18.35 to 48.82.
The secondary factor is the Revenue Growth, contributed 53.58%to the performance.
Overall, the performance of ANIP in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is ANI Pharmaceuticals Inc (ANIP) currently overvalued or undervalued?
What is ANI Pharmaceuticals Inc (ANIP) fair value?
How does ANIP's valuation metrics compare to the industry average?
What is the current P/B ratio for ANI Pharmaceuticals Inc (ANIP) as of Dec 06 2025?
What is the current FCF Yield for ANI Pharmaceuticals Inc (ANIP) as of Dec 06 2025?
What is the current Forward P/E ratio for ANI Pharmaceuticals Inc (ANIP) as of Dec 06 2025?